ZIVO Bioscience, Inc. (ZIVO)
- Previous Close
20.00 - Open
20.24 - Bid 19.60 x 43500
- Ask 20.40 x 36900
- Day's Range
20.24 - 20.24 - 52 Week Range
0.48 - 20.50 - Volume
22 - Avg. Volume
1,306 - Market Cap (intraday)
70.038M - Beta (5Y Monthly) 0.27
- PE Ratio (TTM)
-- - EPS (TTM)
-5.33 - Earnings Date Nov 11, 2024 - Nov 15, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
12.00
ZIVO Bioscience, Inc., a research and development company, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. The company operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health. Its products indications include poultry gut health, bovine mastitis, canine joint health, human immune modification, algal biomass for human consumption, and biomass for supporting skin health / anti-aging. The company was formerly known as Health Enhancement Products, Inc. and changed its name to ZIVO Bioscience, Inc. in October 2014. ZIVO Bioscience, Inc. is headquartered in Bloomfield Hills, Michigan.
www.zivobioscience.comRecent News: ZIVO
View MorePerformance Overview: ZIVO
Trailing total returns as of 10/16/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ZIVO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ZIVO
View MoreValuation Measures
Market Cap
69.21M
Enterprise Value
69.78M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
789.90
Price/Book (mrq)
--
Enterprise Value/Revenue
1.18k
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-1,261.20%
Return on Equity (ttm)
--
Revenue (ttm)
59.32k
Net Income Avi to Common (ttm)
-13.25M
Diluted EPS (ttm)
-5.33
Balance Sheet and Cash Flow
Total Cash (mrq)
2.47k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-18.14k
Research Analysis: ZIVO
View MoreCompany Insights: ZIVO
ZIVO does not have Company Insights